MedPath

苏州中化药品工业有限公司

Ownership
-
Established
1993-04-27
Employees
-
Market Cap
-
Website
https://www.sccpc.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

100

NMPA:100

Drug Approvals

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20244231
Approval Date
Jun 28, 2024
NMPA

Telmisartan and Hydrochlorothiazide Tablets

Product Name
替米沙坦氢氯噻嗪片
Approval Number
国药准字H20247022
Approval Date
Jan 29, 2024
NMPA

Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Sustained-release Tablets

Product Name
西替伪麻缓释片
Approval Number
国药准字H20090113
Approval Date
Sep 28, 2023
NMPA

Calcium Polycarbophil Granules

Product Name
聚卡波非钙颗粒
Approval Number
国药准字H20233989
Approval Date
Aug 1, 2023
NMPA

Itraconazole Capsules

Product Name
伊曲康唑胶囊
Approval Number
国药准字H20123428
Approval Date
Jun 28, 2022
NMPA

Cefalotin Sodium for Injection

Product Name
注射用头孢噻吩钠
Approval Number
国药准字H20073966
Approval Date
May 7, 2022
NMPA

Cefalotin Sodium for Injection

Product Name
注射用头孢噻吩钠
Approval Number
国药准字H20073965
Approval Date
May 7, 2022
NMPA

Cefalotin Sodium for Injection

Product Name
注射用头孢噻吩钠
Approval Number
国药准字H20073967
Approval Date
May 7, 2022
NMPA

Cefepime Hydrochloride for Injection

Product Name
注射用盐酸头孢吡肟
Approval Number
国药准字H20184163
Approval Date
Dec 6, 2021
NMPA

Cefepime Hydrochloride for Injection

Product Name
注射用盐酸头孢吡肟
Approval Number
国药准字H20123259
Approval Date
Dec 6, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.